Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBurping is one of the most commonly reported upper gastrointestinal side effects of Wegovy (semaglutide). The NHS patient information for semaglutide lists eructation — the clinical term for burping — among the known side effects, and participants in the STEP 1 trial reported it at meaningful rates. It tends to peak in the early weeks of treatment and often eases as your body adjusts. These are prescription-only medicines; a clinical assessment determines whether Wegovy is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When the STEP 1 trial (68 weeks, nearly 2,000 adults with obesity) was published in the New England Journal of Medicine, gastrointestinal events were the dominant adverse effects recorded. Nausea led the list, but eructation (burping) featured consistently among upper-GI complaints, and participants in the semaglutide arm reported it at higher rates than those on placebo. The NHS medicines page for semaglutide reflects this, listing burping alongside nausea, vomiting, diarrhoea and constipation as effects to expect.
The reason sits in the pharmacology. Semaglutide activates GLP-1 receptors in the gut, which deliberately slows the rate at which your stomach empties. That's partly how it reduces appetite, meals feel more filling, for longer. The trade-off is that gas produced during digestion has more time to accumulate before it clears. Swallowing air while eating (which most people do more than they realise) compounds this. The result: more frequent, sometimes more forceful, burping.
It does not mean the medicine is harming you. For most people, burping on Wegovy is uncomfortable rather than serious, and the pattern tends to improve once your gut adapts to the new gastric-emptying rate. If you are finding the burping particularly disruptive, that is worth mentioning to whoever is overseeing your treatment, a fuller picture of Wegovy's side-effect profile may also put it in context.
A pattern many people notice: burping settles after the first few weeks at one dose, then returns when the next dose begins. This is expected. Each step up in semaglutide concentration re-triggers the gastric-slowing effect more intensely while your system recalibrates. It is not a signal to stop treatment; it is the same adjustment process repeating at a higher level.
That said, persistent or severe upper-abdominal symptoms deserve attention. The MHRA's safety communications on GLP-1 medicines highlight acute pancreatitis as a rare but serious possibility, recognisable by severe, persistent stomach pain that radiates to the back, sometimes with vomiting. Ordinary burping does not look like this. But if upper abdominal pain becomes intense and does not ease, seek medical help promptly rather than waiting to see whether it passes. You can report any suspected side effect through the MHRA's Yellow Card scheme, which helps regulators track real-world safety signals.
For the vast majority of people, burping with Wegovy sits firmly in the "inconvenient but harmless" category, peaking around the time of a dose change and fading within a week or two. A question our prescribers hear fairly often is whether it means the dose is too high, in most cases, it simply means the dose is new.
You may be reading this because the burping is genuinely bothering you, noisy, frequent, and happening at inconvenient moments. That is a reasonable thing to want to fix, and there are adjustments that actually help. None of these replaces clinical advice, but they are consistent with guidance from NHS weight-management services.
Eating pace matters more than most people expect. Semaglutide already extends the time food spends in your stomach; if you eat quickly, you swallow considerably more air, which has nowhere to go except back up. Slowing down (putting cutlery down between bites) reduces swallowed air substantially. Smaller, more frequent meals reduce the pressure on a slower-emptying stomach. Fizzy drinks, including sparkling water, introduce gas directly; cutting them during the adjustment period often makes a noticeable difference within days.
Some people find that fatty or very rich foods trigger more burping, because fat is one of the strongest signals for slowing gastric emptying. Leaning towards lighter meals while you are adapting to a new dose can smooth the transition. Chewing food thoroughly (which sounds obvious but is genuinely underrated) reduces the gas load before it reaches the stomach. If you are looking at burping as a semaglutide side effect and want to understand it more fully, that covers the underlying causes in greater depth, while information on how to manage burping specifically on Wegovy covers these adjustments in more detail.
If you are considering Wegovy and wondering whether side effects like this make it the wrong choice, the honest answer is that they affect people differently. A full look at how Wegovy works and what treatment involves gives a more complete picture before you decide anything. Treatment is available only on prescription, following a clinical assessment that weighs your individual circumstances. If you are already on treatment and the burping is severe or not settling, speak to your prescribing team, that is exactly what they are there for.
For those thinking about whether a private prescribing service might work for them, understanding your options for accessing Wegovy in the UK is a useful starting point. Or, if you are ready to talk to a prescriber, you can check your eligibility through a free consultation, reviewed the same day by a GPhC-registered prescriber, not a form-processing algorithm.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.